Condition: ccRCC · Clear Cell Renal Cell Carcinoma · Kidney Cancer · Sponsor: NiKang Therapeutics, Inc.
The goal of the Lead-in phase of the study is to evaluate the safety, efficacy, pharmacokinetics (PK) and determine recommended dose for expansion (RDE) of NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy. The goal of the Expansion phase of the study is to evaluate the safety, efficacy, PK at the selected RDE and identify the RP2D for NKT2152 in combination with palbociclib (Doublet) and with palbociclib and sasanlimab (Triplet) in subjects with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who received prior therapy.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California San Diego | La Jolla, California, United States | — |
| Northwestern University - Feinberg School of Medicine | Chicago, Illinois, United States | — |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Michigan-Rogel Cancer Center | Ann Arbor, Michigan, United States | — |
| Nebraska Cancer Specialists | Omaha, Nebraska, United States | — |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | — |
| UT Southwestern Medical Center | Dallas, Texas, United States | — |
| University of Virginia Health System | Charlottesville, Virginia, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05935748